Last reviewed · How we verify
NCT06372665
Safety Observation of the Japanese Encephalitis Vaccine Given With a Primary Immunization
trial in Japanese Encephalitis in 15,357 participants. Completed in 30 April 2025.
30 April 2025
Quick facts
| Lead sponsor | Liaoning Chengda Biotechnology CO., LTD |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 15,357 |
| Start date | 1 January 2024 |
| Primary completion | 30 April 2025 |
| Estimated completion | 30 April 2025 |
| Sites | 1 location across China |
Conditions studied
- Japanese Encephalitis — all drugs for Japanese Encephalitis →
Sponsor
Liaoning Chengda Biotechnology CO., LTD — full company profile →
Who can join
8 Months and older, any sex, with Japanese Encephalitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single-arm, non-randomized, open-label post-marketing safety observation study. The purpose of this study is to investigate the safety of JEV-I given with primary immunization in a large amount of healthy children aged 8 months and older.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
An active surveillance study of adverse events following to Japanese encephalitis inactivated vaccine (JE-I) in Jiangsu Province, China, 2024-2025.
Liu L, Zhang L, Hu R, Kang G, et al · · 2026 · PMID 41980877 · DOI 10.1080/14760584.2026.2653748
Verify or expand the search:
- PubMed search for NCT06372665
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Japanese Encephalitis
Currently open trials in the same condition.
- NCT07358910 — Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective · recruiting
- NCT06678373 — Monitoring JE Antibody Levels in Healthy Populations and Immunization Strategy in Low-Prevalence Areas · Phase 4 · active not recruiting
Other Liaoning Chengda Biotechnology CO., LTD trials
Trials by the same sponsor.
- NCT07120464 — Clinical Study on Immunogenicity and Safety of Lyophilized Vero Cell-Derived Human Rabies Vaccine in Special Populations · recruiting
- NCT06678373 — Monitoring JE Antibody Levels in Healthy Populations and Immunization Strategy in Low-Prevalence Areas · Phase 4 · active not recruiting
- NCT06331702 — Immunogenicity of Japanese Encephalitis Vaccine Co-administered With Measles-Mumps-Rubella Vaccine (MMR) · Phase 4 · completed
- NCT06825312 — Immunogenicity, Safety, and Antibody Persistence of Different Immunization Strategies Against Japanese Encephalitis · Phase 4 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06372665 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Liaoning Chengda Biotechnology CO., LTD
- Last refreshed: 28 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06372665.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing